MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
3.270
-0.240
-6.84%
Opening 14:31 02/27 EST
OPEN
3.410
PREV CLOSE
3.510
HIGH
3.500
LOW
3.200
VOLUME
42.07K
TURNOVER
--
52 WEEK HIGH
20.59
52 WEEK LOW
2.450
MARKET CAP
13.87M
P/E (TTM)
-0.3034
1D
5D
1M
3M
1Y
5Y
1D
Cellectar BioSciences Inc. published an update to their financial calendar
Reuters · 2d ago
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
Barchart · 2d ago
Five new option listings and fourteen option delistings on February 23rd
TipRanks · 4d ago
Weekly Report: what happened at CLRB last week (0216-0220)?
Weekly Report · 4d ago
Cellectar Biosciences Announces Broad Expansion Of Its Global IP Estate, Including Newly Issued Patents Across Europe, Asia-Pacific, The Middle East, And The Americas
Benzinga · 02/17 13:12
Cellectar Biosciences Secures New Patents to Strengthen Global Cancer Drug Portfolio
Reuters · 02/17 13:05
Cellectar Biosciences Expands Global Intellectual Property Estate
Barchart · 02/17 07:05
Weekly Report: what happened at CLRB last week (0209-0213)?
Weekly Report · 02/16 10:18
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.